Appia Bio
Latest round
- Series A
Last raised
- May 2021
Total raised
- $52M
Investors
- 4
About Appia Bio
Founded in 2020 and headquartered in Los Angeles, US, Appia Bio develops unique T cell therapies for cancer treatment.Appia Bio specializes in developing universal allogeneic cell therapies utilizing invariant NKT and gamma delta T cells. These therapies are designed to target various cancers, offering potential curative solutions by leveraging the unique properties of engineered T cells. The company's core product offerings are based on a technology platform that combines stem cell biology with advanced T cell development techniques.Appia Bio’s revenue model is structured around partnerships and collaborations with medical institutions and research organizations that seek cancer therapies. The company is targeting expansion into new markets, with a focus on regions in Europe and Asia, aiming for significant progress by 2023. Additionally, Appia Bio is working on launching new products designed to enhance treatment options for cancer patients.
Who invested in Appia Bio
4 investors across 1 round
See all investors in Appia Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
May 11, 2021
Amount
$52M
Investors
Questions about Appia Bio
Who invested in Appia Bio?
Appia Bio has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Appia Bio raised?
Appia Bio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Appia Bio last raise money?
Appia Bio's most recent round on record is a Series A, in May 2021.
What does Appia Bio do?
Founded in 2020 and headquartered in Los Angeles, US, Appia Bio develops unique T cell therapies for cancer treatment.
Where is Appia Bio headquartered?
Appia Bio is headquartered in Los Angeles, US.
Which VCs invest in companies like Appia Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Appia Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Appia Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.